Ongoing Reglan Litigation — New Appellate Ruling

by Searcy Denney Scarola Barnhart & Shipley

Earlier this week, a Missouri appeals court issued an opinion that will hopefully have a significant impact on ongoing litigation against the manufacturers of metoclopramide, the generic version of Reglan.  In this latest case, the appeals court found that plaintiffs Franzman and Niceley, both of whom suffered tardive dyskinesia after ingesting metoclopramide on a long-term basis, could proceed with their individual lawsuits against the generic drug manufacturer for negligence claims based on a failure to timely update the warning label for their drugs.  This finding is based upon the generic drug manufacturer’s failure to comply with its legal duty to promptly update the generic drug’s warning label when the warnings for the brand name version are updated.  This is one of several cases where state courts have rejected the defendants’ claims that generic drug manufacturer preemption under federal law immunizes them from all liability, even when the drug companies have failed to comply with their own legal obligations under state and federal law.  The highest appellate courts in Iowa and Alabama have also recently issued opinions in favor of injured plaintiffs in Reglan cases, finding that the patients should be permitted to litigate some negligence claims against the generic drug manufacturers and those claims are not preempted by federal law.   Dozens of federal courts have refused to hold the generic drug manufacturers liable under essentially identical facts involving patients with metoclopramide-induced tardive dyskinesia.

Metoclopramide --ReglanReglan, also known as metoclopramide, was first marketed as a brand name drug in the early 1970s by Wyeth.  The drug was approved for use short-term in patients with gastroparesis and other serious swallowing disorders.  Reglan increases muscle contractions in the digestive tract, which helps to improve the speed at which the stomach empties into the intestines.  Over the years, generic formulations came to market, and the brand name version of Reglan was rarely prescribed.   As more generic drug companies sought sales for their formulations of Reglan, there was an aggressive marketing effort to expand using the drug.  The generic manufacturers encouraged doctors and patients to use metoclopramide to treat Gastroesophageal Reflux Disease (GERD) or heartburn, chronic conditions that required treatment for a time far over the four-month time limit considered safe for Reglan.

This surge in sales, sadly, led to an epidemic of patients with tardive dyskinesia.  Reglan is one of several drugs that cause tardive dyskinesia.  Tardive dyskinesia (TD) is a movement disorder characterized by involuntary movements.  The disease often affects the facial muscles with patients having uncontrollable grimacing, twitching, and chewing.   The patient’s ability to walk, move, and take care of themselves can also be affected.  Tardive dyskinesia is often initially misdiagnosed as Parkinson’s Disease.  On February 26, 2009, the FDA issued a press release noting a further enhancement in the warning label for Reglan and warned physicians not to prescribe the drug for more than a few months, as the risks of serious neurological impairment outweighed the benefits of the drug to patients.

Under current federal law, Wyeth, as the brand name manufacturer, had an obligation to update the warning label for Reglan to reflect changing information regarding the risks associated with the medication and monitoring adverse event data reported by healthcare providers and injured patients.  Generic drug manufacturers, under our current flawed drug safety laws, are required to merely copy the brand name label.  Since Wyeth has not been actively selling Reglan for years, the drug label has not been updated as frequently as it should have been and the brand name manufacturer is not actively engaged in adverse event monitoring.   Wyeth updated the warning label for Reglan in 2004 to reflect that the drug should not be prescribed for over 12 months, as studies have shown that the risk of developing tardive dyskinesia increases substantially when the drug is used long-term.  Some generic drug manufacturers failed to follow federal and state laws and did not update their warning labels to reflect this vital safety information after the 2004 change to the warning label and package insert for brand name Reglan.   Current state and federal laws will not generally hold the brand name manufacturer responsible for injuries caused by a generic formulation, although the brand name manufacturer has some control over minimizing potential harm to these patients through proper labeling of their products.

In the past, the manufacturers of generic Reglan and other drugs have enjoyed almost-complete immunity in light of the Bartlett and Mensing decisions from the United States Supreme Court and other federal court case law. Over the past few years, dozens of seriously injured plaintiffs have had their lawsuits for serious personal injuries caused by generic drugs kicked out of court.  Several thousand adults and children who developed catastrophic neurological injuries caused by Reglan have been waiting for more than a year for decisions on pending appeals in the Pennsylvania state appellate courts where Pliva, Teva, Morton Grove, UDL Laboratories, and other generic manufacturers of Reglan have sought case dismissals.   This unfortunate (and avoidable) development in our legal system has left a gaping hole, where significantly injured plaintiffs are being denied justice and have no legal recourse against the giant drug companies who are responsible for (and were in a position to prevent) their injuries.

While there have been some efforts to fix this injustice in Congress, many victims, especially those who were harmed by Reglan, have been largely left without recourse.  Ultimately, the costs associated with this defective drug will be borne by we, as the patients require expensive medical care and long-term nursing care often covered by Medicare and Medicaid.  The costs to our economy of defective drugs such as this could easily exceed hundreds of millions of dollars, and those companies who are profiting from the sale of these dangerous products are not shouldering the burden of these costs.  If generic drug manufacturers will not be held liable for the harm they inflict on patients, then we should not be forced by our government and health insurers to ingest their generic pharmaceuticals.

Want to learn more about generic drug preemption?  You can do so at the Take Justice Back web site, which includes the stories patients who have died or been severely harmed by generic drugs, such as Reglan and Darvocet, and have been left with no recourse in our court system.  You can also help to fix this problem by signing the petitions available on the Take Justice Back web site (over 20,000 consumers have already done so).  Also, please ask your members of

Congress to address this problem before more Americans are harmed.  The Patient Safety and Drug Labeling Improvement Act (S. 2295 and H.R. 4384), introduced in 2012 but not enacted, would help to address this critical safety issue.  The FDA is also considering changes to its guidelines which will help, but not completely eliminate, the injustices created by generic drug preemption.  As indicated by the United States Supreme Court in the past, only Congress can fix this mess.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Searcy Denney Scarola Barnhart & Shipley | Attorney Advertising

Written by:

Searcy Denney Scarola Barnhart & Shipley

Searcy Denney Scarola Barnhart & Shipley on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.